<div id="readability-page-1"><div><ul><li>Bio Rad Laboratories Inc reported quarterly adjusted earnings of $2.26​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $2.01. The mean expectation of six analysts for the quarter was for earnings of $1.93 per share. Wall Street expected results to range from $1.56 to $2.20 per share.</li><li>Revenue rose 0.5% to $653.00 million from a year ago; analysts expected $651.30 million. </li><li>The company reported a quarterly loss of $341.9 million.</li><li>Bio Rad Laboratories Inc shares had risen by 17.8% this quarter and gained 0.6% so far this year.</li></ul>FORECAST CHANGES<ul><li>The mean earnings estimate of analysts had risen by about 15.8% in the last three months.​ </li><li>In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.</li></ul>RECOMMENDATIONS<ul><li>The current average analyst rating on the shares is &#34;buy&#34; and the breakdown of recommendations is 4 &#34;strong buy&#34; or &#34;buy,&#34; 2 &#34;hold&#34; and no &#34;sell&#34; or &#34;strong sell.&#34; The average consensus recommendation for the medical equipment, supplies &amp; distribution peer group is also &#34;buy&#34; </li><li>Wall Street's median 12-month price target for Bio Rad Laboratories Inc is $325.00, about 1.7% below its last closing price of $319.47</li></ul>This summary was machine generated from LSEG data October 29 at 10:17 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)<div><table><tbody><tr><td>QUARTER ENDING</td><td>ESTIMATE </td><td>ACTUAL</td><td>BEAT, MET, MISSED</td></tr><tr><td>Sep. 30 2025 </td><td>1.93</td><td>2.26</td><td>Beat</td></tr><tr><td>Jun. 30 2025 </td><td>1.73</td><td>2.61</td><td>Beat</td></tr><tr><td>Mar. 31 2025 </td><td>1.81</td><td>2.54</td><td>Beat</td></tr><tr><td>Dec. 31 2024 </td><td>2.87</td><td>2.90</td><td>Beat</td></tr></tbody></table></div></div></div>

Bio Rad Laboratories Inc reported Q3 adjusted earnings of $2.26 per share, exceeding last year's $2.01 and analysts' expectations of $1.93. Revenue increased by 0.5% to $653 million, slightly above the forecast of $651.30 million. Despite a quarterly loss of $341.9 million, shares rose 17.8% this quarter. Analysts' earnings estimates have increased by 15.8% over the past three months, with a consensus rating of "buy". The median 12-month price target is $325, 1.7% below the last closing price of $319.47.

Bio Rad Laboratories Inc reports results for the quarter ended September 30 - Earnings Summary